FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281609045> ?p ?o ?g. }

• W4281609045 endingPage "e16536" @default.
• W4281609045 startingPage "e16536" @default.
• W4281609045 abstract "e16536 Background: mUC is an aggressive disease with limited overall survival. Recently, immunotherapy with checkpoint inhibitors (ICI) has dramatically improved outcomes but with limited response rates and overall survival. ADC were designed with the intent to deliver potent cytotoxic drugs selectively to antigen-expressing tumor cells by linking cytotoxins to mAbs and have emerged as a new option of treatment with promising results. We aimed to realize a systematic review of efficacy, treatment-related AEs (trAEs) and impact on quality of life of ADC in mUC. Methods: A systematic review of the literature has been performed in January 2022 using Pubmed and Embase database according to the Preferred Reported Items for Systematic Reviews and Meta-analyses (PRISMA) statement. After excluding review, duplicate and non-relevant articles, 10 clinical trials were included in the analysis. The search method involved querying for the terms bladder carcinoma or urothelial carcinoma with any of the following: enfortumab vedotin (EV), sacituzumab govitecan (SG), antibody-drug conjugate. Only prospective clinical trials were included. Results: The systematic review yielded 1103 records using MEDLINE (741 records) and EMBASE (362 records). Ultimately, 9 phase 1, 2 or 3 clinical trials with 1355 patients were selected for inclusion and 4 drugs were identified: Enfortumab vedotin (EV), sacituzumab govitecan (SG), an anti-HER2 compound (RC48-ADC), and an anti- SLITRK6 drug (ASG-15ME). Efficacy outcomes are presented in table 1. Phase 2 trials have reported promising response rates in mUC and one randomized phase 3 trial showed the superiority of EV vedotin over CT after failure to platinum-based CT and ICI with improvement in overall survival. TRAEs of any grade occurred in more than 90% of patients in phase 2 or 3 trials, with high rates of discontinuation (table 2). TRAEs of special interest related to EV were rash, neuropathy, and hyperglycemia. SG is associated with diarrhea and hematologic toxicity. Data from phase 2 and 3 trials of EV suggest no impact on quality of life and an improvement in some parameters. Conclusions: ACDs represent a very promising new option for the treatment of mUC. A phase 3 trial confirmed the superiority of EV over CT after platinum and IO failure. A high incidence of potential adverse events was observed in phase 2 and 3 trials, including rash, neutropenia, hematologic toxicity, and neuropathy. Practitioners’ oncologists should be aware of potential adverse events and optimal management. Quality of life is preserved during the treatment with EV." @default.
• W4281609045 created "2022-06-12" @default.
• W4281609045 creator A5000621664 @default.
• W4281609045 creator A5010913087 @default.
• W4281609045 creator A5031550729 @default.
• W4281609045 creator A5032356135 @default.
• W4281609045 creator A5038077329 @default.
• W4281609045 creator A5058849092 @default.
• W4281609045 creator A5083331837 @default.
• W4281609045 creator A5083351538 @default.
• W4281609045 creator A5090516084 @default.
• W4281609045 date "2022-06-01" @default.
• W4281609045 modified "2023-09-27" @default.
• W4281609045 title "Efficacy and toxicity of antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review." @default.
• W4281609045 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e16536" @default.
• W4281609045 hasPublicationYear "2022" @default.
• W4281609045 type Work @default.
• W4281609045 citedByCount "0" @default.
• W4281609045 crossrefType "journal-article" @default.
• W4281609045 hasAuthorship W4281609045A5000621664 @default.
• W4281609045 hasAuthorship W4281609045A5010913087 @default.
• W4281609045 hasAuthorship W4281609045A5031550729 @default.
• W4281609045 hasAuthorship W4281609045A5032356135 @default.
• W4281609045 hasAuthorship W4281609045A5038077329 @default.
• W4281609045 hasAuthorship W4281609045A5058849092 @default.
• W4281609045 hasAuthorship W4281609045A5083331837 @default.
• W4281609045 hasAuthorship W4281609045A5083351538 @default.
• W4281609045 hasAuthorship W4281609045A5090516084 @default.
• W4281609045 hasConcept C121608353 @default.
• W4281609045 hasConcept C126322002 @default.
• W4281609045 hasConcept C143998085 @default.
• W4281609045 hasConcept C159654299 @default.
• W4281609045 hasConcept C17744445 @default.
• W4281609045 hasConcept C189708586 @default.
• W4281609045 hasConcept C199539241 @default.
• W4281609045 hasConcept C203014093 @default.
• W4281609045 hasConcept C204232928 @default.
• W4281609045 hasConcept C2775949291 @default.
• W4281609045 hasConcept C2777325958 @default.
• W4281609045 hasConcept C2777701055 @default.
• W4281609045 hasConcept C2778191690 @default.
• W4281609045 hasConcept C2779473830 @default.
• W4281609045 hasConcept C2780030458 @default.
• W4281609045 hasConcept C2780352672 @default.
• W4281609045 hasConcept C2911057145 @default.
• W4281609045 hasConcept C3019882237 @default.
• W4281609045 hasConcept C31760486 @default.
• W4281609045 hasConcept C535046627 @default.
• W4281609045 hasConcept C542903549 @default.
• W4281609045 hasConcept C70905583 @default.
• W4281609045 hasConcept C71924100 @default.
• W4281609045 hasConceptScore W4281609045C121608353 @default.
• W4281609045 hasConceptScore W4281609045C126322002 @default.
• W4281609045 hasConceptScore W4281609045C143998085 @default.
• W4281609045 hasConceptScore W4281609045C159654299 @default.
• W4281609045 hasConceptScore W4281609045C17744445 @default.
• W4281609045 hasConceptScore W4281609045C189708586 @default.
• W4281609045 hasConceptScore W4281609045C199539241 @default.
• W4281609045 hasConceptScore W4281609045C203014093 @default.
• W4281609045 hasConceptScore W4281609045C204232928 @default.
• W4281609045 hasConceptScore W4281609045C2775949291 @default.
• W4281609045 hasConceptScore W4281609045C2777325958 @default.
• W4281609045 hasConceptScore W4281609045C2777701055 @default.
• W4281609045 hasConceptScore W4281609045C2778191690 @default.
• W4281609045 hasConceptScore W4281609045C2779473830 @default.
• W4281609045 hasConceptScore W4281609045C2780030458 @default.
• W4281609045 hasConceptScore W4281609045C2780352672 @default.
• W4281609045 hasConceptScore W4281609045C2911057145 @default.
• W4281609045 hasConceptScore W4281609045C3019882237 @default.
• W4281609045 hasConceptScore W4281609045C31760486 @default.
• W4281609045 hasConceptScore W4281609045C535046627 @default.
• W4281609045 hasConceptScore W4281609045C542903549 @default.
• W4281609045 hasConceptScore W4281609045C70905583 @default.
• W4281609045 hasConceptScore W4281609045C71924100 @default.
• W4281609045 hasFunder F4320324142 @default.
• W4281609045 hasIssue "16_suppl" @default.
• W4281609045 hasLocation W42816090451 @default.
• W4281609045 hasOpenAccess W4281609045 @default.
• W4281609045 hasPrimaryLocation W42816090451 @default.
• W4281609045 hasRelatedWork W2546607321 @default.
• W4281609045 hasRelatedWork W2554546702 @default.
• W4281609045 hasRelatedWork W2772794544 @default.
• W4281609045 hasRelatedWork W2808310746 @default.
• W4281609045 hasRelatedWork W2809077554 @default.
• W4281609045 hasRelatedWork W2904110710 @default.
• W4281609045 hasRelatedWork W2961042511 @default.
• W4281609045 hasRelatedWork W3118005002 @default.
• W4281609045 hasRelatedWork W3202746846 @default.
• W4281609045 hasRelatedWork W4281609045 @default.
• W4281609045 hasVolume "40" @default.
• W4281609045 isParatext "false" @default.
• W4281609045 isRetracted "false" @default.
• W4281609045 workType "article" @default.